Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan

Anish Patel, COO of Enliven Therapeutics, sold 6,667 shares of common stock at an average price of $21.4394, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of 6,667 shares of common stock on March 7, 2025.
• The sale was executed at a weighted average price of $21.4394, with individual trades ranging from $20.99 to $22.25.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 30, 2024.
• Following the transaction, Patel directly owns 323,310 shares indirectly through The Patel / Dong Family Trust Dated August 24, 2017, for which Patel serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was conducted under a pre-arranged 10b5-1 trading plan, suggesting it was not based on any new material information.

Industry Context

Sales by company insiders are routinely monitored by investors. Sales under a 10b5-1 trading plan are less likely to be interpreted as a negative signal, as these plans are pre-arranged and designed to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates